. Author manuscript; available in PMC: 2023 Sep 1.

Published in final edited form as: J Clin Neurophysiol. 2020 Dec 8;39(6):459–465. doi: 10.1097/WNP.0000000000000803

TABLE 2.

Relationship Between EEG Features and Drug Resistance

Feature	Responsive Patients With Feature, N (%)	Resistant Patients With Feature, N (%)	OR of Resistant-To-Responsive (95% CI)	P
GSW	66 (91.7)	29 (93.5)	1.3 (0.3–6.9)	1.0
PSW	40 (55.6)	21 (67.7)	1.7 (0.7–4.1)	0.28
GPT	7 (9.7)	9 (29.0)	3.8 (1.3–11.4)	0.02
GPFA	4 (5.6)	6 (19.4)	4.1 (1.1–15.7)	0.06
GPT or GPFA	8 (11.1)	10 (32.3)	3.8 (1.3–10.9)	0.02
GLVFA	0 (0.0)	2 (6.5)	—	0.09
Focal discharges	1 (1.4)	3 (9.7)	7.6 (0.8–76.3)	0.08
Focal slowing	3 (4.2)	2 (6.5)	1.6 (0.3–10.0)	0.64

A higher OR implies greater prevalence of the feature in drug-resistant patients.

95% CI, 95% confidence interval; GLVFA, generalized low-voltage fast activity; GPFA, generalized paroxysmal fast activity; GPT, generalized polyspike train; GSW, generalized spike–wave; OR, odds ratio; PSW, polyspike-and-wave; —, not estimable.